Transgene S.A.

Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
  • TickerTNG
  • ISINFR0005175080
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Thanks to a better fundamental star rating, TRANSGENE sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to TRANSGENE (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date May 17, 2019, the closing price was EUR 3.01 and its expected value was estimated at EUR 2.96.

Expert Corporate Governance Service (ECGS)

Transgène - Assemblée Générale des actionnaires du 22 mai 2019

Proxinvest attire l'attention des actionnaires sur différents points : Tout d'abord les rémunérations attribuées et attribuables au Président Directeur Généraet Directeur Général Délégué manquent clairement de transparence. L'actionnaire ne peut pas appréhender l'exigence des rémunérations variables. (Résolutions 6 à 9) Ensuite les conventions réglementées semblent désavantageuses pour les actionnaires minoritaires, ce qui entraine une recommandation de vote négative sur le rapport présenté en résolution 15. Nous signalons l’élection de Mr Hedi Ben Brahim en remplacement de Mr Alain Mérieux...

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - TRANSGENE : Nouvel accord de collaboration validant Invir-IO - ACHAT, OC 4,2€ (vs 4,0€)

Hugo Solvet

TRANSGENE: Transgene signs an agreement with AstraZeneca | CORPORATE | EUR6.5(+117%)

TRANSGENE - CORPORATE | EUR6.5(+117%) Transgene signs an agreement with AstraZeneca A landmark deal in oncolytic viruses A recognition for the Invir IO platform Transgene will get a USD10m upfront payment Cash visibility until Q4 2020 – Buy reiterated

Martial Descoutures ...
  • Pierre Corby

Transgene : Growing credibility for Invir.IO

>Collaboration with AstraZeneca - Transgene announced this morning that it had signed a collaboration agreement with AstraZeneca. The aim is to co-develop five armed oncolytic vaccinia virus candidates based on its proprietary platform Invir.IO. As part of this agreement, Transgene will receive an initial payment of $ 10m. This could be rapidly supplemented by preclinical success milestone payments of up to $ 3m. The other financial terms were not specified in the pre...

Martial Descoutures ...
  • Pierre Corby

Transgene : De plus en plus de crédibilité pour Invir.IO

>Une collaboration avec AstraZeneca - Transgene annonce ce matin avoir signé une collaboration avec AstraZeneca. Celle-ci a pour but de codévelopper cinq virus oncolytiques multi-armés issus de sa plateforme propriétaire Invir.IO. Dans le cadre de cet accord, Transgene recevra un paiement initial d'un montant de 10 M$. Celui-ci pourrait être complété rapidement de 3 M$ supplémentaires en fonction de franchissement d’étapes précliniques. La suite des modalités financiè...

Daniel Wilkinson

Transgene - Defining data from lead assets by year-end

Key inflection points from lead assets Pexa-Vec, TG4010 and TG4001 by year-end will continue to inform the validity of Transgene’s IO strategy. Notably, a futility analysis expected mid-year for the Phase III trial with Pexa-Vec (+sorafenib) in first-line hepatocellular carcinoma (HCC) and efficacy data from the Phase II TG4010 (+nivolumab + chemotherapy) trial in first-line non-small cell lung cancer (NSCLC) will be key to driving value in 2019. Early-stage development continues with both the expansion of its Invir.IO collaboration with BioInvent and the announcement of the first product cand...

Alexandre Iatrides ...
  • Emmanuel Matot
  • Jean-François Granjon
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 05/02/2019

...

Alexandre Iatrides ...
  • Emmanuel Matot
  • Jean-François Granjon
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 02/05/2019

...

Alfred Glaser ...
  • Delphine Brault
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 03/06/2019

...

Alfred Glaser ...
  • Delphine Brault
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 06/03/2019

...

Jeremy Garnier ...
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 09/20/2018

...

Thanks to a better fundamental star rating, TRANSGENE sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to TRANSGENE (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date May 17, 2019, the closing price was EUR 3.01 and its expected value was estimated at EUR 2.96.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Transgène - Assemblée Générale des actionnaires du 22 mai 2019

Proxinvest attire l'attention des actionnaires sur différents points : Tout d'abord les rémunérations attribuées et attribuables au Président Directeur Généraet Directeur Général Délégué manquent clairement de transparence. L'actionnaire ne peut pas appréhender l'exigence des rémunérations variables. (Résolutions 6 à 9) Ensuite les conventions réglementées semblent désavantageuses pour les actionnaires minoritaires, ce qui entraine une recommandation de vote négative sur le rapport présenté en résolution 15. Nous signalons l’élection de Mr Hedi Ben Brahim en remplacement de Mr Alain Mérieux...

Matthieu DRIOL

Analyse court terme - TRANSGENE SA : La tendance est haussière.

La tendance est haussière. Les cours progressent encore, mais la tendance s'affaiblit. La prochaine résistance est à 3,250 €. La rupture de 2,760 € mettrait la tendance en danger.

Matthieu DRIOL

Short term view - TRANSGENE SA : The trend is bullish.

The trend is bullish. Prices are still making progress but the trend is slowing down. The next resistance is at €3.250. The break of €2.760 would endanger the trend.

Matthieu DRIOL

Analyse court terme - TRANSGENE SA : La tendance est haussière.

La tendance est haussière. Les cours progressent encore, mais la tendance s'affaiblit. La prochaine résistance est à 3,250 €. La rupture de 2,760 € mettrait la tendance en danger.

Matthieu DRIOL

Short term view - TRANSGENE SA : The trend is bullish.

The trend is bullish. Prices are still making progress but the trend is slowing down. The next resistance is at €3.250. The break of €2.760 would endanger the trend.

Valérie GASTALDY

Analyse moyen terme - TRANSGENE SA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 2,270 €, puis 1,642 €. Le franchissement de 5,350 € remettrait en cause la suite de la baisse.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch